GoodRx Expands Access to Eli Lilly and Company’s New Oral GLP-1, Foundayo™, and Zepbound® KwikPen® with Self-Pay Pricing at More Than 70,000 Pharmacies Nationwide

Key Takeaways

• Foundayo priced at $149/month via GoodRx self‑pay model
• Zepbound KwikPen available for $299/month at 70k pharmacies
• GoodRx partners with Eli Lilly to launch direct‑to‑consumer pricing
• Transparent cash pricing addresses insurance gaps for GLP‑1 therapies

Pulse Analysis

The GLP‑1 class has become a cornerstone of modern obesity treatment, with both injectable and oral formulations driving rapid growth. GoodRx’s decision to list Eli Lilly’s newly approved oral agent, Foundayo, at $149 per month marks the first large‑scale, consumer‑direct pricing for an oral GLP‑1 in the United States. By leveraging its extensive pharmacy network, GoodRx can deliver the medication to patients nationwide, offering a convenient alternative to traditional insurance‑driven channels that often involve high copays or prior‑authorization hurdles.

Direct‑to‑consumer pricing models are gaining traction as manufacturers confront uneven insurance coverage for weight‑loss drugs. GoodRx’s transparent cash‑price approach gives self‑pay patients a clear, upfront cost, reducing financial uncertainty and encouraging earlier treatment initiation. The $299 per month price for Zepbound KwikPen, coupled with nationwide availability, further illustrates how pharmaceutical firms are using platforms like GoodRx to reach consumers who might otherwise be excluded from therapy due to coverage gaps. This strategy also helps manufacturers collect real‑world usage data while building brand loyalty outside the pharmacy‑benefit‑manager ecosystem.

For Eli Lilly, the partnership accelerates market entry for both Foundayo and Zepbound, positioning the company ahead of competitors still reliant on insurance pathways. The pricing tiers are competitive with other GLP‑1 options, potentially capturing price‑sensitive segments and expanding the overall addressable market. As more weight‑management drugs receive FDA approval, the success of GoodRx’s model could set a precedent for future launches, prompting other pharma firms to adopt similar consumer‑direct pricing structures to drive adoption and revenue growth.